Michael Grey

Mr. Michael G.
Grey is an Executive Chairman at Theolytics Ltd., an Executive Chairman at Plexium, Inc., a Chairman at Mirum Pharmaceuticals, Inc., an Executive Chairman at Spruce Biosciences, Inc., a Chairman at Sorriso Pharmaceuticals, Inc. and a Venture Partner at Pappas Capital LLC.
He is on the Board of Directors at OnKure Therapeutics, Inc. and Biothera, Inc. Mr. Grey was previously employed as an Executive Chairman by Curzion Pharmaceuticals, Inc., an Executive Chairman by Ziarco Group Ltd., an Executive Chairman by Ziarco Pharma Ltd., an Independent Director by Mirati Therapeutics, Inc., an Executive Chairman by Reneo Pharmaceuticals, Inc., a Lead Independent Director by Horizon Pharma, Inc., a Lead Independent Director by Horizon Therapeutics Ltd. (Ireland), a President & Chief Executive Officer by Lumena Pharmaceuticals, Inc., a President & Chief Executive Officer by Auspex Pharmaceuticals, Inc., an Independent Non-Executive Director by BioMarin Pharmaceutical, Inc., a President & Chief Executive Officer by SGX Pharmaceuticals, Inc., a Non-Executive Chairman by IDM Pharma, Inc., a President, Chief Executive Officer & Director by Trega Biosciences, Inc., a President by Biochem Therapeutic, Inc., a President & Chief Operating Officer by Ansan Pharmaceuticals, Inc., a President & Chief Operating Officer by Ansan, Inc., a Vice President-Corporate Development by Glaxo, Inc., and a Vice President-Corporate Development by Glaxo Holdings Plc.
He also served on the board at Amplyx Pharmaceuticals, Inc., Selventa, Inc., Achillion Pharmaceuticals, Inc., Balance Therapeutics, Inc., Biothera Pharmaceuticals, Inc. (Delaware), Epimmune, Inc. and San Diego Venture Group.
He received his undergraduate degree from The University of Nottingham.